Fri, Dec 19, 2014, 9:41 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • jacosa jacosa Sep 25, 2013 11:47 PM Flag

    Interest in JAK1 specific agents

    I've been at The International Celiac Disease Symposium for the last few days. During a panel discussion on treatment, Thomas Waldmann (a VERY big name in the field) mentioned that he sure would like to have a highly specific JAK1 inhibitor to play around with. So on the break, I showed him the ACR abstract. Seems he's been asking Incyte and other companies what they have cooking pretty regularly, and the answer is always "We can't tell you anything before the public announcement." He's most interested. In addition to CD, he's interested in the possibilities of JAK1 inhibition in various T-cell lymphomas (interesting problem: taken together, there are a lot of cases of T-cell lymphomas. But practically every individual case is a separate subtype. How do you design a trial? What do you want on the label?) I don't know what else is cooking out there, but he'd also like a clean JAK3 inhibitor to play with.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INCY
76.86-0.19(-0.25%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.